Entheon Acquires Pre-Testing Genetics Platform For Psychedelic Treatment

Psychedelics biotech company Entheon Biomedical Corp. (CSE: ENBI) has purchased biotech company HaluGen Life Sciences Inc. in an all-stock transaction.

Entheon acquired 100% of HaluGen in exchange for 5.1 million Entheon shares.

Why Genetic Testing Is Important: Psychedelic compounds have gained significant attention in recent years for their potential to treat multiple mental health conditions including major depressive disorder, anxiety, PTSD and addiction. 

However, psychedelic drugs have been …

Full story available on Benzinga.com

More Entheon Acquires Pre-Testing Genetics Platform For Psychedelic Treatment